{
  "event": {
    "ticker": "AGIO",
    "company": "Agios Pharmaceuticals, Inc.",
    "drug": "mitapivat (AG-348; marketed as PYRUKYND for PK deficiency and AQVESME for thalassemia; brand for sickle cell disease not yet disclosed)",
    "application_type": "sNDA",
    "indication": "Sickle cell disease (RISE UP population: age >=16), filed under the accelerated approval pathway with hemoglobin response as the surrogate endpoint; REIGNITE is the confirmatory Phase 3 trial",
    "pdufa_date": "2026-11-01"
  },
  "display": {
    "company": "Agios",
    "drug": "mitapivat",
    "indication_en": "Sickle cell disease",
    "indication_zh": "镰状细胞病"
  },
  "probability_approval": 0.87,
  "confidence": "medium",
  "base_rate_used": 0.95,
  "key_factors": [
    {
      "factor": "Mixed pivotal trial: the hemoglobin surrogate was met but the pain-crisis co-primary endpoint was not, in a disease where the Hb surrogate has been discredited",
      "direction": "-",
      "step": "large",
      "evidence": "In RISE UP Phase 3 (n=207, 2:1), hemoglobin response was 40.6% vs 2.9% (p<0.0001). The annualized sickle-cell pain crisis rate was 2.62 vs 3.05 (p=0.12, not significant), and the PROMIS-Fatigue key secondary endpoint also missed. Accelerated approval needs the Hb rise to be 'reasonably likely' to predict clinical benefit. Voxelotor's 2019 accelerated approval rested on the same >=1 g/dL Hb endpoint and was withdrawn in 2024 after imbalances in deaths and pain crises. This is a supplement, so the 95% base rate assumes routine efficacy; this file is closer to a contested new-indication review.",
      "source": "Agios press release 2025-11-19 (RISE UP topline); Am J Hematol 2025 voxelotor withdrawal analysis; HCPLive sNDA coverage"
    },
    {
      "factor": "The FDA itself steered Agios toward accelerated approval, agreed a confirmatory trial and granted priority review",
      "direction": "+",
      "step": "medium",
      "evidence": "Agios had the full RISE UP results in hand at its Q1 2026 pre-sNDA meeting, where 'the FDA recommended submission of a proposal for a confirmatory clinical trial to support U.S. accelerated approval'. REIGNITE (about 159 patients, 2:1, primary endpoint transfusion-free status from week 4 to week 52) has dosed its first patient, which meets the FDORA requirement that the confirmatory trial be under way. The sNDA was submitted in May 2026 and accepted with priority review. The PDUFA date of 1 November 2026 was assigned by the FDA.",
      "source": "Agios press release 2026-03-31 (pre-sNDA meeting); Agios press release 2026-07-07 (priority review); SEC 10-Q filed 2026-07-30"
    },
    {
      "factor": "Safety in sickle cell disease is clean and the clinical signals point in the right direction, unlike voxelotor",
      "direction": "+",
      "step": "small",
      "evidence": "Serious TEAEs were 20.3% on mitapivat vs 29.0% on placebo, and there were no treatment-related deaths. Coverage of the EHA plenary reports deaths of 3 (2.2%) vs 2 (2.9%). Management says the liver injury seen in thalassemia, which carries a boxed warning and REMS there, was not seen in the sickle cell trials. Patients on mitapivat needed transfusions less often (23.9% vs 40.6%) and received fewer RBC units (0.70 vs 1.59). The pain-crisis rate trended lower, and Hb responders had fewer pain crises, ER visits and hospitalizations, though those responder analyses are not randomized comparisons.",
      "source": "Agios EHA 2026 plenary release 2026-06-13; EMJ EHA 2026 coverage; Agios Q2 2026 earnings call (MarketBeat/TradingView summary)"
    },
    {
      "factor": "The drug is already approved and made at commercial scale, so CMC risk is minimal",
      "direction": "+",
      "step": "small",
      "evidence": "Mitapivat has been approved since 2022 (PK deficiency) and was approved for thalassemia in December 2025. The SCD dose (100 mg twice daily) matches the thalassemia dose, so no new formulation or facility should be needed.",
      "source": "Drugs@FDA NDA216196; SEC 10-Q filed 2026-07-30"
    },
    {
      "factor": "No advisory committee called, but the FDA's view of accelerated approval is unsettled",
      "direction": "-",
      "step": "small",
      "evidence": "About four weeks before the PDUFA date, no hematology advisory committee has been scheduled, which suggests the division does not see a need for outside input. On the other side, FDA leadership turned over through 2026, and the agency has become more sceptical of surrogate-based approvals. A late change of position cannot be ruled out. Agios's own follow-on PK activator, tebapivat, failed in its SCD Phase 2 in July 2026 (Hb response 29-47% vs 33% on placebo). The FDA could read that as a reason for caution about the class's Hb effect.",
      "source": "FDA advisory committee calendar search 2026-10-04; Agios press release 2026-07-21 (tebapivat)"
    }
  ],
  "manufacturing_risk": {
    "level": "low",
    "why": "This is a supplement for a commercially manufactured small-molecule tablet that has already passed FDA review twice (2022, 2025). No new facility or formulation is expected."
  },
  "what_would_change_my_mind": [
    "The FDA calls an advisory committee, or Agios discloses a major amendment or a 3-month extension (the extension changes only the date)",
    "The FDA signals that hemoglobin is not an acceptable surrogate in SCD, or requires more confirmatory evidence before approval",
    "New safety information from the RISE UP open-label extension or REIGNITE (deaths, pain-crisis or liver events)",
    "Disclosure of label negotiations or a REMS decision (up)"
  ],
  "summary_en": "We put approval of Agios's mitapivat for sickle cell disease at 87%, below the ~95% base rate for supplements. The Phase 3 RISE UP trial met its hemoglobin endpoint (40.6% vs 2.9%) but missed its pain-crisis co-primary. The filing relies on hemoglobin as an accelerated-approval surrogate, the same surrogate that failed with voxelotor. In its favour: the FDA itself recommended the accelerated-approval route after seeing the data, agreed a confirmatory trial that is now running, and granted priority review. Safety in sickle cell is clean, with fewer serious adverse events than placebo, no liver injury signal and fewer transfusions. Manufacturing risk is minimal. Confidence is medium.",
  "summary_zh": "我们估计 Agios 的 mitapivat 用于镰状细胞病获批概率为 87%，低于补充申请约 95% 的基准。三期 RISE UP 试验达到血红蛋白终点（40.6% 对 2.9%），但另一主要终点疼痛危象未达统计显著。本次申请以血红蛋白作为加速审批的替代终点，与已撤市的 voxelotor 相同。有利因素：FDA 看过数据后主动建议走加速审批，已同意确证性试验且试验已启动，并给予优先审评。镰状细胞病中安全性良好：严重不良事件少于安慰剂，无肝损伤信号，输血减少。药品已商业化生产，生产风险很低。把握度中等。",
  "sources": [
    "https://www.sec.gov/Archives/edgar/data/1439222/000143922226000118/agio-20260630.htm (Agios 10-Q filed 2026-07-30: sNDA May 2026, priority review, PDUFA 2026-11-01, REIGNITE design)",
    "https://www.sec.gov/Archives/edgar/data/0001439222/000143922226000115/agio-73026xfyxex991earning.htm (Agios 8-K 2026-07-30, Q2 2026 results)",
    "https://www.globenewswire.com/news-release/2026/03/31/3265325/31990/en/agios-advances-mitapivat-toward-potential-u-s-accelerated-approval-in-sickle-cell-disease-following-pre-snda-meeting-with-fda.html (pre-sNDA meeting outcome)",
    "https://www.nasdaq.com/press-release/us-fda-grants-priority-review-agios-snda-mitapivat-sickle-cell-disease-2026-07-07",
    "https://www.globenewswire.com/news-release/2025/11/19/3190791/31990/en/agios-announces-topline-results-from-rise-up-phase-3-trial-of-mitapivat-in-sickle-cell-disease.html (RISE UP topline)",
    "https://www.biospace.com/press-releases/agios-showcases-rise-up-phase-3-results-at-eha-2026-plenary-session-reinforcing-strong-anti-hemolytic-profile-of-mitapivat-in-sickle-cell-disease (2026-06-13)",
    "https://www.emjreviews.com/hematology/news/mitapivat-improves-anaemia-in-sickle-cell-disease/ (serious AEs 20.3% vs 29.0%)",
    "https://www.agios.com/wp-content/uploads/2026/06/EHA_RISE_UP_Ph3_Plenary_Slides_D8a_final.pdf (EHA 2026 plenary slides; death counts as reported in coverage)",
    "https://www.tradingview.com/news/marketbeat:bdbe8991d094b:0-agios-pharmaceuticals-q2-earnings-call-highlights/ (no hepatocellular injury in SCD trials; REMS may not be warranted)",
    "https://www.hcplive.com/view/mitapivat-snda-fda-accelerated-approval-sickle-cell-disease",
    "https://onlinelibrary.wiley.com/doi/10.1002/ajh.27635 (voxelotor withdrawal and Hb surrogate lessons)",
    "https://www.hcplive.com/view/agios-ends-tebapivat-development-in-sickle-cell-disease-after-phase-2 (tebapivat SCD Phase 2, July 2026)"
  ],
  "zh": {
    "indication": "镰状细胞病（SCD；RISE UP 研究人群：年龄 ≥16 岁），以血红蛋白应答为替代终点按加速批准路径申报；REIGNITE 为确证性 3 期试验",
    "key_factors": [
      {
        "factor": "关键试验结果喜忧参半：血红蛋白替代终点达成，但疼痛危象共同主要终点未达成，而在该疾病中血红蛋白替代终点的可信度已受到质疑",
        "evidence": "在 RISE UP 3 期试验（n=207，2:1 随机）中，血红蛋白应答率为 40.6% 对 2.9%（p<0.0001）。年化镰状细胞疼痛危象发生率为 2.62 对 3.05（p=0.12，未达统计学显著），PROMIS-Fatigue 关键次要终点亦未达成。加速批准要求 Hb 升高“合理可能”预测临床获益。Voxelotor 于 2019 年基于同样的 Hb 升高 ≥1 g/dL 终点获得加速批准，2024 年因死亡和疼痛危象失衡而撤市。本申请为补充申请（sNDA），因此 95% 的基准获批率默认疗效没有争议；而本申请更接近一次存在争议的新适应症审评。"
      },
      {
        "factor": "FDA 本身引导 Agios 走加速批准路径，同意了确证性试验，并给予优先审评",
        "evidence": "Agios 在 2026 年第一季度召开 sNDA 申报前会议时已掌握 RISE UP 的完整结果，会上“FDA 建议提交一项确证性临床试验方案，以支持美国加速批准”。REIGNITE（约 159 例患者，2:1 随机，主要终点为第 4 周至第 52 周无输血状态）已完成首例患者给药，满足 FDORA 关于确证性试验须已在进行中的要求。sNDA 于 2026 年 5 月提交，并获受理及优先审评。PDUFA 目标日期 2026 年 11 月 1 日由 FDA 确定。"
      },
      {
        "factor": "与 voxelotor 不同，该药在镰状细胞病中安全性良好，临床信号方向也一致向好",
        "evidence": "严重治疗期间不良事件（TEAE）发生率为 mitapivat 组 20.3%，安慰剂组 29.0%，且无治疗相关死亡。有关 EHA 全体会议报告的报道显示，死亡分别为 3 例（2.2%）和 2 例（2.9%）。管理层表示，在地中海贫血中观察到的肝损伤（该适应症因此带有黑框警告及风险评估与减低策略（REMS））未在镰状细胞病试验中出现。mitapivat 组患者输血频率更低（23.9% 对 40.6%），接受的红细胞单位数更少（0.70 对 1.59）。疼痛危象发生率呈下降趋势，Hb 应答者的疼痛危象、急诊就诊和住院次数也更少，但这些应答者分析并非随机比较。"
      },
      {
        "factor": "该药已获批且已实现商业化规模生产，化学、生产与控制（CMC）风险极低",
        "evidence": "Mitapivat 自 2022 年起获批（丙酮酸激酶（PK）缺乏症），并于 2025 年 12 月获批用于地中海贫血。SCD 剂量（100 mg，每日两次）与地中海贫血剂量相同，因此应无需新剂型或新生产设施。"
      },
      {
        "factor": "未召开专家咨询委员会会议，但 FDA 对加速批准的立场尚不明朗",
        "evidence": "距 PDUFA 目标日期约四周，FDA 尚未安排血液学专家咨询委员会会议，这表明审评部门认为无需外部意见。另一方面，FDA 领导层在 2026 年间持续更迭，该机构对基于替代终点的批准也愈发审慎，不能排除其在后期改变立场。Agios 自家的后续 PK 激活剂 tebapivat 于 2026 年 7 月在 SCD 2 期试验中失败（Hb 应答率 29-47%，安慰剂组为 33%）。FDA 可能将此视为对该类药物 Hb 效应保持谨慎的理由。"
      }
    ],
    "manufacturing_risk_why": "本申请是针对一款已商业化生产的小分子片剂的补充申请，该产品已两次通过 FDA 审评（2022 年、2025 年）。预计无需新的生产设施或剂型。",
    "what_would_change_my_mind": [
      "FDA 召开专家咨询委员会会议，或 Agios 披露重大修改或 3 个月延期（延期仅改变日期）",
      "FDA 表示血红蛋白不是 SCD 中可接受的替代终点，或要求在批准前提供更多确证性证据",
      "来自 RISE UP 开放标签扩展研究或 REIGNITE 的新安全性信息（死亡、疼痛危象或肝脏事件）",
      "披露说明书谈判或 REMS 决定（概率上调）"
    ]
  },
  "recorded_at": "2026-10-04T19:58:04+00:00"
}